Ventana Biotech Inc

Ventana Biotech Inc

August 05, 2009 07:44 ET

Combatting Obesity With Appetite-Suppressing Chewing Gum

LONDON, UNITED KINGDOM--(Marketwire - Aug. 5, 2009) - Ventana Biotech Inc ("Ventana") (PINK SHEETS:VNTA), a biotechnology company that is developing a appetite-suppressing chewing gum, today released information about its groundbreaking appetite-regulating biotechnology.

With Ventana's proprietary Anti-Obesity Chewing Gum, users can safely control their appetites without experiencing any of the common side effects common with appetite suppressing drugs. The Gum works by stimulating the body's own natural hormones that regulate appetite. Early indications show the Gum is able to reduce appetite by between 15 and 25 percent. Ventana continues to perfect this promising biotechnology that uses chemicals already produced by the patient's own body, therefore having no side-effects whatsoever.

The outlook for anti-obesity treatments such as that of Ventana's is promising, as the anti-obesity market continues to grow, while concurrently, the availability of successful patents is lacking. Morgan Stanley estimates the market for drugs combating Type 2 Diabetes (strongly correlated to obesity) to be in excess of $35 billion by 2012.

When successful trials for Ventana's Anti-Obesity Chewing Gum have been concluded, the patent will be out-licensed to Big Pharma companies such as GlaxoSmithKline, Novo Nordisk, AstraZeneca who then pay milestone and licensing fees to Ventana Biotech for use of the patents.

The royalty cash-flow from a successful anti-obesity drug is estimated at $1.5 - 1.7 billion.

About Ventana Biotech Inc

Ventana is positioning itself as the leading bioscience company in the development and commercial licensure of novel therapeutic anti-obesity drug treatment. The company leverages cutting-edge research collaborations to achieve breakthroughs in innovative anti-obesity treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.


Statements about Ventana's future expectations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as the term is defined in the Private Litigation Reform Act of 1995. Ventana's actual results could differ materially from expected results. Ventana does not undertake any obligation to update forward-looking statements to reflect subsequently occurring events or circumstances. Should events occur which materially affect any comments made within this objective; Ventana will appropriately inform the public.

For more information about Ventana Biotech Inc please contact

Contact Information

  • Ventana Biotech Inc
    Janne Christensen, CEO
    BCB 1 Bachstrasse
    Butschwil CH-9606
    Mobile: +44 7930 732 426